WESTFORD, Mass., March 31, 2016 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced that 17 scientific abstracts and three ePosters have been accepted for presentation at the 36th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS). The event is taking place today through April 3, 2016 at the Sheraton Boston Hotel & Hynes Convention Center in Boston, Massachusetts.
The presentations will detail data from research programs for a range of indications addressed by Cynosure's energy-based technologies, including non-invasive fat reduction, skin rejuvenation, melasma, facial photoaging, tattoo removal and genitourinary syndrome of menopause (GSM).
Two late-breaking abstracts evaluating Cynosure's MonaLisa Touch® for the treatment of GSM will be presented as part of the first-ever abstract session on women's health conducted at the ASLMS annual conference.
"Our technology is at the forefront of some of the latest research and newest energy-based applications being presented at ASLMS," said Cynosure Chairman and CEO Michael Davin. "Whether it's non-invasive body contouring, gynecological disorders or the treatment of tattoos, pigmentation and other skin conditions, today we have the strongest product portfolio – addressing the widest spectrum of indications – in our history. The breadth of research associated with our technology underlines our leadership in helping to shape the future of aesthetic medicine."
The presentations will highlight studies involving Cynosure's PicoSure®, SculpSure® and MonaLisa Touch® laser platforms. Here is the schedule:
PicoSure
Title: A 1064nm, 532nm, and 755nm Laser System for the Treatment of Unwanted Tattoos
Authors: Bradley Bloom, Hamad Alabdulrazzaq, Yoon-Soo Cindy Bae, Jeremy Brauer, Julia Neckman, Leonard Bernstein, Elliot Weiss, Robert Anolik, Roy Geronemus, Laser & Skin Surgery Center of New York, New York, NY
Date and Time: Friday, April 1 at 1:07 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 37
Title: Unwanted Periorbital Tattoos Safely And Effectively Treated with Picosecond 755nm Alexandrite Laser
Authors: Julia Neckman, Jeremy Brauer, Roy Geronemus, Laser & Skin Surgery Center of New York, New York, NY
Date and Time: Friday, April 1 at 1:35 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 41
Title: Safety and Efficacy of Picosecond Alexandrite Laser on the Treatment of Mixed Melasma on Asian Patients
Authors: Victoria Belo, Johanna Cristina Munoz, Jennifer Roslyn Sison-De Leon, Belo Medical Group, San Juan City, Philippines, Makati City, Philippines
Date and Time: Friday, April 1 at 1:42 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 42
Title: 755nm Picosecond Laser for Skin Rejuvenation in Chinese
Authors: Samantha Y.N. Shek, Chi K. Yeung, Johnny C.Y. Chan, Henry H.L. Chan, The University of Hong Kong, Hong Kong, China; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA
Date and Time: Friday, April 1 at 3:00 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 43
Title: Picosecond Laser for Facial Rejuvenation Using a Compressed Treatment Interval
Authors: Jeffrey Dover, Kenneth Arndt, Shilpi Khetarpal, Heidi Prather, Shraddha Desai, Laura Kruter, Joaninha Depina, Kathleen Petrell, SkinCare Physicians, Chestnut Hill, MA
Date and Time: Friday, April 1 at 3:07 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 44
Title: Treatment of Neck Laxity Using a Picosecond 755nm Alexandrite Laser
Authors: Anne Zhuang, Suzanne Kilmer, University of California Davis; The Laser and Skin Surgery Center of Northern California, Sacramento, CA
Date and Time: Friday, April 1 at 3:14 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 45
Title: Pilot Study of 755nm Alexandite Picosecond Laser for the Treatment of Striae Distensae: A Clinical and Histopathological Study in Asian Patients
Authors: Victoria Belo, Guada Santos-Capiz, Michelle Villaneuva, Belo Medical Group, San Juan City, Philippines
Date and Time: Friday, April 1 at 3:21 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 46
Title: The Immediate Clinical and Thermal Findings Associated with the Use of a Picosecond Alexandrite Laser with a Flat and a Fractional Optic
Authors: Emil Tanghetti, Amanda Knox, Carolyn Hamann, Center for Dermatology and Laser Surgery, Sacramento, CA
Date and Time: Friday, April 1 at 3:28 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 47
Title: Comparative Cutaneous Histology From the Treatment Using a Picosecond Alexandrite And Nd: YAG Laser With A Fractional Optics
Author: Emil Tanghetti, Center for Dermatology and Laser Surgery, Sacramento, CA
Date and Time: Friday, April 1 at 3:35 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: LB6
Title: A Prospective Split-Face Study of the Picosecond Alexandrite Laser with Specialized Lens Array for Facial Photoaging in Chinese
Authors: Tong Lin, Yiping Ge, Lifang Guo, Rong Zeng, Department of Cosmetic Laser Surgery, Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China
Date and Time: Friday, April 1 at 3:49 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: LB8
Title: Interesting Variety of Clinical Observations with Picosecond Laser Technology
Author: Christine Dierickx, Skinperium, Boom, Belgium
Date and Time: Friday, April 1 at 4:03 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 48
ePoster: Treatment of Melasma via a Novel Alexandrite PicoSecond Laser Regimen Using Both the Deffractive Lens Array and Standard Optics
Authors: Robert Weiss, David McDaniel, Margaret Weiss, Karen Beasley, Christian Halvorson, Anne Mahoney, Kerry Shaughnessy
ePoster: Treatment of Medication Induced Pigmentation with a 755nm PicoSecond Laser
Authors: Klaus Hoffmann, Silias Soemantri
SculpSure
Title: A Multi-center Study of a Non-invasive 1060nm Diode Laser for Fat Reduction of the Flanks and Abdomen 6 Month Follow Up
Authors: Lawrence Bass, Bruce Katz, Sean Doherty, Bass Plastic Surgery; JUVA Skin & Laser Center, New York, NY; Boston Plastic Surgery Associates, Concord, MA
Date and Time: Saturday, April 2 at 1:30 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 49
Title: Objective Evaluation of a Non-invasive Fat Reduction with a 1060nm Diode Laser for Treatment of the Thighs and Back
Authors: Bruce Katz, Lawrence Bass, Sean Doherty, JUVA Skin & Laser Center; Bass Plastic Surgery, New York, NY; Boston Plastic Surgery Associates, Concord, MA
Date and Time: Saturday, April 2 at 1:37 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 50
Title: Ultrasound Findings in Fat Following a 1060nm Non-invasive Diode Laser – Correlation with Anatomic Findings
Authors: David McDaniel, Robert Weiss, Sean Doherty, Bo Chen, Kerry Shaughnessy, Margaret Weiss, Karen Beasley, Christian Halvorson, Anne Mahoney, McDaniel Laser and Cosmetic Center, Virginia Beach, VA; Maryland Skin and Vein Institute, Hunt Valley, MD; Boston Plastic Surgery Associates, Concord, MA; Cynosure, Westford, MA
Date and Time: Saturday, April 2 at 1:44 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 51
Title: Clinical Evaluation of Fat Reduction Treatment of the Flanks and Abdomen with a Non-Invasive 1060nm Diode Laser: A Multicenter Study
Authors: Robert Weiss, David McDaniel, Sean Doherty, Margaret Weiss, Karen Beasley, Christian Halvorson, Anne Mahoney, Kerry Shaughnessy, Maryland Skin and Vein Institute, Hunt Valley, MD; McDaniel Laser and Cosmetic Center, Virginia Beach, VA; Boston Plastic Surgery Associates, Concord, MA
Date and Time: Saturday, April 2 at 1:51 p.m.
Session: Cutaneous Applications
Location: Hynes Auditorium
Abstract: 52
ePoster: In Vivo and In Vitro Tissue Temperature during a Non-Invasive 1060nm Hyperthermic Fat Treatment
Authors: Sean Doherty, Bo Chen
MonaLisa Touch
Title: Treatment Of Coexistent Lichen Sclerosus and Vulvo-Vaginal Atrophy with Fractional Co2 Laser Therapy
Author: Jeffrey Dell, Institute for Female Pelvic Medicine, Knoxville, TN
Date and Time: Saturday, April 2 at 5:11 p.m.
Session: Women's Health
Location: Hynes 107
Abstract: LB 39
Title: An Assessment of the Safety and Efficacy of the Smartxide2 Fractional Co2 Laser for the Treatment of Vulvovaginal Atrophy
Authors: Patrick Lang, Sana Hussain, Mickey Karram, The Christ Hospital, Cincinnati, OH
Date and Time: Saturday, April 2 at 5:18 p.m.
Session: Women's Health
Location: Hynes 107
Abstract: LB 40
About Cynosure, Inc.
Cynosure develops, manufactures, and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through non-invasive and minimally invasive laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve vaginal health. Cynosure also markets radiofrequency energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, Mexico, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including Cynosure's expectations with respect to timing and success of product launches, regulatory clearances and international registrations, as well as other statements containing the words, "believes," "looks forward," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the market price of Cynosure's stock prevailing from time to time, the nature of other investment opportunities presented to the Company from time to time, the Company's cash flow from operations, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, including the MonaLisa Touch and SculpSure products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K for the 12 months ended December 31, 2015, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
Contact:
Scott Solomon
Senior Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
SOURCE Cynosure, Inc.